Literature DB >> 28120124

Metabolic engineering of Bacillus subtilis for biosynthesis of heparosan using heparosan synthase from Pasteurella multocida, PmHS1.

Xiaofei Chen1, Rong Chen1, Xiaoxiao Yu1, Dongyang Tang1, Wenbing Yao2, Xiangdong Gao3.   

Abstract

Heparosan, the capsular polysaccharide discovered in many pathogenic bacteria, is a promising material for heparin preparation. In this study, the Pasteurella multocida heparosan synthase 1 (PmHS1) module was used to synthesize heparosan with controlled molecular weight, while tuaD/gtaB module or gcaD module was responsible for UDP-precursors production in Bacillus subtilis 168. After metabolic pathway optimization, the yield of heparosan was as high as 237.6 mg/L in strain containing PmHS1 module and tuaD/gtaB module, which indicated that these two modules were key factors in heparosan production. The molecular weight of heparosan varied from 39 to 53 kDa, which indicated that heparosan molecular weight could be adjusted by the amount of PmHS1 and the ratio of two UDP precursors. The results showed that it would be possible to produce safe heparosan with appropriate molecular weight which is useful in heparin production.

Entities:  

Keywords:  Heparosan; Metabolic engineering; Molecular weight control; Recombinant Bacillus subtilis

Mesh:

Substances:

Year:  2017        PMID: 28120124     DOI: 10.1007/s00449-016-1732-4

Source DB:  PubMed          Journal:  Bioprocess Biosyst Eng        ISSN: 1615-7591            Impact factor:   3.210


  2 in total

1.  High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification.

Authors:  Payel Datta; Li Fu; Paul Brodfuerer; Jonathan S Dordick; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-22       Impact factor: 4.813

Review 2.  Enzymatic Synthesis of Glycans and Glycoconjugates.

Authors:  Thomas Rexer; Dominic Laaf; Johannes Gottschalk; Hannes Frohnmeyer; Erdmann Rapp; Lothar Elling
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.